Vivani Medical, Inc. VANI
1.13 USD -0.02 (-1.74%)
At closeNov 11, 2026, 4:00 PM EST
1.13 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
1.12 Day range 1.16
0.923 52-week range 1.66
- YTD
- -8.13%
- 1 year
- -20.98%
News
benzinga.com Vivani Medical Q2 EPS $(0.07) Beats $(0.08) Estimate Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 41.67 percent increase over losses of…
benzinga.com Vivani Medical To Allow Novo Nordisk To Evaluate NPM-139, The Company’s Semaglutide Drug Implant NPM-139, which utilizes Vivani’s NanoPortal™ platform technology, is under development for chronic weight management. There are no exclusivity provisions for NPM-139, or Vivani’s proprietary…
benzinga.com ClearOne To Acquire Vivani Medical Subsidiary Cortigent For 12.5M Shares Of CLRO Worth ~$40.4M; ClearOne To File S-1 Seeking To Raise $10M-$15M Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that it has entered into a definitive…
benzinga.com Vivani Medical Receives Approval From Australian Human Research Ethics Committee Bellberry To Initiate SLIM-1, A Phase 1 Clinical Trial Of Semaglutide Implant NPM-139 Vivani CEO Adam Mendelsohn, Ph.D., stated, "HREC approval to initiate SLIM-1 in Australia marks an important moment for our Company, clearing the way for near-term, mid-2026, initiation. We are eager…
benzinga.com Lake Street Initiates Coverage On Vivani Medical with Buy Rating, Announces Price Target of $4 Lake Street analyst Thomas Flaten initiates coverage on Vivani Medical (NASDAQ:VANI) with a Buy rating and announces Price Target of $4.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Vivani Medical Q4 EPS $(0.09) Beats $(0.10) Estimate. Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.10) by 10 percent. This is a 18.18 percent increase over losses of $(0.11)…
benzinga.com Vivani's Brain Implant Helps Blind Patients See Light And Movement In 6-Year Study Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that Cortigent, Inc.…- benzinga.com Vivani Medical Q3 EPS $(0.11), Inline Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
- benzinga.com Vivani Medical Expects To Spin Off Cortigent Unit; Starts Clinical Development Of NPM-139 Semaglutide Implant In Obesity, Chronic Weight Management In 2026 Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a biopharmaceutical company developing miniaturized, ultra long-acting drug implants, today reported financial results for the third…
benzinga.com Vivani Medical Announces Company Presentation, Unveils Obesity Market Strategy With New GLP-1 Implant Technology https://d1io3yog0oux5.cloudfront.net/_8b0e72ba9731939ad4ef3d445345826e/vivanimedical/db/2227/20875/pdf/Vivani+Corporate+Presentation+_+102925.pdf- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Vivani Sets October 8 Record Date For Spin-Off Of Cortigent, To Trade Under Nasdaq Ticker 'CRGT' Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Vivani Medical Plans To Initiate Phase 1 Clinical Study In NPM-139 Semaglutide Implant Program In First Half Of 2026, Pending Regulatory Clearance NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administrationFirst-in-human Phase 1 study is expected to initiate in the first half of 2026, pending regulatory
- benzinga.com HC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.
- benzinga.com Vivani Medical Q2 EPS $(0.12) Misses $(0.10) Estimate Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 20 percent. This is a 20 percent decrease over losses of $(0.10)…
benzinga.com EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss from a single dose.- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Vivani Medical Announces The Appointment Of Anthony Baldor As Chief Financial Officer Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the appointment of…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com Vivani Medical Q1 EPS $(0.11) Misses $(0.10) Estimate Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.10) by 10 percent. This is a 8.33 percent increase over losses of…- benzinga.com HC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.
- benzinga.com Vivani Medical Expands Collaboration With Okava Pharmaceuticals To Include Dogs In Development Of OKV-119, A Long-Acting Glp-1 Therapy For Weight Management, Diabetes and Other Cardiometabolic Conditions ALAMEDA, Calif. and SAN FRANCISCO, April 15, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature,…
benzinga.com EXCLUSIVE: Vivani Medical Collaborates With Okava To Expand Development Of GLP-1 Therapy For Dogs Vivani Medical and Okava expand GLP-1 therapy research to dogs, aiming to advance long-acting treatments for cardiometabolic conditions.- benzinga.com HC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.
- benzinga.com Vivani Medical Q4 2024 GAAP EPS $(0.11), Inline, As Of December 31, 2024, Vivani Had Cash, Cash Equivalents And Restricted Cash Totaling $19.7M, Additional $8.25M Equity Financing Which Secures Solid Financial Position Into Q2 Of 2026 Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a 8.33 percent increase over losses of $(0.12) per share from the same…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.
benzinga.com EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing Vivani Medical's NPM-139 semaglutide implant showed steady drug release and nearly 20% weight loss in preclinical studies, supporting long-term weight management.
benzinga.com EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management. Top-line results are expected by mid-2025.- benzinga.com HC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.
benzinga.com EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value Vivani Medical plans to spin off Cortigent into a separate public company, aiming to expand neurostimulation technology while focusing on its drug implants.- benzinga.com EXCLUSIVE: Vivani Medical Initiates First Human Clinical Trial With GLP-1 Implant For Weight Loss In Australia Vivani Medical launches first-in-human trial of its exenatide implant in Australia, aiming to support chronic weight management with innovative GLP-1 technology.
- benzinga.com "Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News https://www.bloomberg.com/news/articles/2024-12-13/ozempic-craze-appears-to-be-curbing-us-obesity-epidemic
- benzinga.com 'ADA Advises Against Using Compounded GLP-1 RA Medications' - Medscape https://www.medscape.com/viewarticle/ada-advises-against-using-compounded-glp-1-ra-medications-2024a1000m0u?form=fpf
- benzinga.com Vivani Medical Q3 2024 GAAP EPS $(0.11), Inline Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate.
benzinga.com HC Wainwright & Co. Initiates Coverage On Vivani Medical with Buy Rating, Announces Price Target of $3 HC Wainwright & Co. analyst Yi Chen initiates coverage on Vivani Medical (NASDAQ:VANI) with a Buy rating and announces Price Target of $3.- benzinga.com Reported Earlier, 'Novo Nordisk's Ozempic and Wegovy, long in shortage, are now listed as available by FDA; It remains unclear how the update could affect patients as well as compounders' - STAT News https://www.statnews.com/2024/10/30/novo-nordisk-ozempic-wegovy-fda-available-or-in-shortage/
- benzinga.com EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia Vivani Medical receives approval for the first human trial of its GLP-1 obesity implant in Australia. The LIBERATE-1 trial will assess safety, tolerability, and weight loss outcomes, with data…
- benzinga.com EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity Vivani Medical reports promising preclinical liver fat reduction results with its exenatide implant for obesity, showing potential as a differentiated treatment option. The LIBERATE-1 clinical trial…
- benzinga.com Vivani Medical Q2 2024 Adj EPS $(0.10) Beats $(0.12) Estimate Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.12) by 16.67 percent.
- benzinga.com Pineapple Financial And 1 Other Stock Under $1 Insiders Are Buying
- benzinga.com Vivani Medical And 2 Other Stocks Under $2 Insiders Are Buying
- benzinga.com EXCLUSIVE: Vivani Medical Outlines Plans To Kickstart First Clinical Study For Miniature GLP-1 Obesity Implant Program This Year Vivani Medical plans to start the first clinical study of the NPM-115 program in Australia in Q4 2024. The study will evaluate a 6-month GLP-1 implant for chronic weight management in obese or…
- benzinga.com Why Signet Jewelers Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- benzinga.com Why GLP-1 Developer Vivani Medical's Stock Is Climbing Vivani Medical shares are trading higher Thursday after the company announced the FDA cleared the Investigational New Drug application and lifted the clinical hold on NPM-119.
- benzinga.com EXCLUSIVE: Vivani Medical's Type 2 Diabetes Treatment NPM-119 Subdermal Implant's IND Gains FDA Clearance For Clinical Use (UPDATED) Vivani Medical cleared FDA for NPM-119 trial in type 2 diabetes. LIBERATE-1 will assess safety, tolerability, & pharmacokinetics. NPM-115 & NPM-139 also in development for weight management.
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of…